Holen Sie sich die Stockscreener-App
9.21
2.33%
0.21
Handel nachbörslich:
9.21
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - Investing News Network
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Nasus Pharma Is Targeting a Validated Market With a Potentially Superior Intranasal Delivery Approach - GuruFocus
Levin Capital Strategies L.P. Increases Holdings in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
CenterBook Partners LP Invests $5.15 Million in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
How Recent Regulatory Twists Are Reframing The Story For ARS Pharmaceuticals (SPRY) - Yahoo Finance
How Ars Pharmaceuticals Inc. (SPRY) Affects Rotational Strategy Timing - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 7%Here's What Happened - MarketBeat
Practice Advances: A focus on neffy® (epinephrine nasal spray) - Patient Care Online
ARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Aberdeen Group plc - MarketBeat
Got $300? 2 Biotech Stocks to Buy and Hold Forever - Yahoo Finance
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
What are ARS Pharmaceuticals Inc.’s earnings expectations2025 Risk Factors & Verified Momentum Stock Alerts - mfd.ru
Will ARS Pharmaceuticals Inc announce a stock splitTrade Volume Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Is ARS Pharmaceuticals Inc. stock vulnerable to regulatory risksSwing Trade & Weekly High Return Opportunities - mfd.ru
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha
Why hedge funds are buying ARS Pharmaceuticals Inc. stockJuly 2025 Reactions & High Win Rate Trade Alerts - mfd.ru
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® at 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting - Investing News Network
Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan
Why ARS Pharmaceuticals Inc. stock remains on watchlists2025 Macro Impact & Weekly Return Optimization Alerts - mfd.ru
Market Moves: Is INHDs ROE strong enoughWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
(SPRY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Will ARS Pharmaceuticals Inc. stock recover after earningsWeekly Loss Report & Capital Efficiency Focused Ideas - mfd.ru
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Eyeing a 171% Upside with Innovative Allergy Solutions - DirectorsTalk Interviews
How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe - Yahoo Finance
Aquestive leaps, despite receiving CRL for Anaphylm NDA - The Pharma Letter
ARS Pharma Gets Positive CHMP Opinion For 1 Mg EURneffy Nasal Spray - Nasdaq
Needle-free allergy rescue for kids wins key EU support - Stock Titan
US FDA declines to approve Aquestive's oral drug for allergic reactions - Reuters
Targets Report: Will OceanPal Inc benefit from geopolitical trendsCPI Data & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Sells 208,886 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Weekly Recap: Will ARS Pharmaceuticals Inc announce a stock splitJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Cut to Strong Sell at Zacks Research - MarketBeat
Repeat Offenders: Neffy, Anktiva Promotions Draw Another US FDA Untitled Letter After Crackdown - Citeline News & Insights
OPDP doubles up on ARS’s Neffy - Medical Marketing and Media
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Responsive Playbooks and the SPRY Inflection - Stock Traders Daily
Update Recap: Will ARS Pharmaceuticals Inc stock recover after earningsJuly 2025 Snapshot & Capital Efficient Trade Techniques - baoquankhu1.vn
Pullback Watch: Will ARS Pharmaceuticals Inc stock recover after earnings2025 Top Gainers & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
ARS Pharmaceuticals Reports Q3 2025 Financial Results - MSN
What ARS Pharmaceuticals (SPRY)'s neffyinSchools California Expansion Means For Shareholders - Sahm
Valuation Update: Is ARS Pharmaceuticals Inc a top pick in the sectorInsider Selling & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Rallies: Can ARS Pharmaceuticals Inc generate free cash flowJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Pullback Watch: Is ARS Pharmaceuticals Inc attractive at current valuationJuly 2025 Action & Weekly Consistent Profit Watchlists - baoquankhu1.vn
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free ... - nrtoday.com
California K-12 Schools Now Eligible for neffyinSchools - GlobeNewswire
ARS Pharmaceuticals, Inc. (SPRY) Investor Outlook: Analyzing the 171% Upside Potential for This Biotech Stock - DirectorsTalk Interviews
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray - simplywall.st
Understanding the Setup: (SPRY) and Scalable Risk - Stock Traders Daily
Is ARS Pharmaceuticals Inc a top pick in the sector2025 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Sell Signal: Is ARS Pharmaceuticals Inc stock a falling knife or bargain buy2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Targets Report: What analysts say about ARS Pharmaceuticals Inc stock2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 12.3%Should You Sell? - MarketBeat
Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump - Yahoo Finance
There's No Escaping ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) Muted Revenues Despite A 25% Share Price Rise - 富途牛牛
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - simplywall.st
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Finviz
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Sahm
2.25%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):